Navigation Links
SoluBest Appoints Michael Sheckler, MBA, as CEO
Date:9/10/2008

TEL AVIV, Israel, Sept. 10 /PRNewswire/ -- SoluBest Ltd., a privately held, clinical stage developer of a novel solubilizing technology, has appointed Michael Sheckler, MBA, as CEO. Mr. Sheckler brings over 25 years of pharmaceutical experience to SoluBest.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080910/NEW068LOGO )

Mr. Sheckler began his career with the Ross Division of Abbott Laboratories, selling nutritional and pharmaceutical products. During his time there, he served in a variety of sales roles, winning numerous awards. As a market research analyst, Mr. Sheckler was responsible for the market assessment and product launch plans for several line extensions.

Mr. Sheckler left Ross in 1999 to join Bespak, Inc., a drug delivery technology company, where he held several roles of increasing responsibility. As Head of Marketing for the newly created Nasal Drug Delivery business, he was instrumental in launching the business stream, assessing and growing new business opportunities in the U.S., and developing and implementing the launch and marketing plans for new products.

Upon leaving Bespak, Mr. Sheckler joined Intranasal Technology, Inc, a Kentucky-based nasal drug delivery company as Director of Business Development where he successfully created and implemented a business development and marketing communications strategy positioning the company for its entry into the nasal analgesia market.

Prior to joining SoluBest, Mr. Sheckler served as Vice President of Business Development at Javelin Pharmaceuticals. During his tenure, he realized annual savings of $350M through recognizing and negotiating a new contract manufacturing agreement and strengthened a successful $32M fundraiser through serving an integral role in investor conferences and road shows.

Mr. Sheckler graduated from Indiana University and obtained his MBA from The Fuqu
'/>"/>

SOURCE SoluBest Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Affitech Appoints Dr. Keith McCullagh as Chairman
3. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
4. Algenol Biofuels Appoints Chief Science Officer
5. Axial Biotech appoints new Vice President of Strategic Initiatives
6. Insulet Appoints Bill Arthur as Vice President of Business Development
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
9. Landauer, Inc. Appoints Two New Members to Board of Directors
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015  Ardelyx, Inc. (NASDAQ: ARDX ), ... and metabolic diseases, today announced that Annalisa ... Board of Directors. Dr. Jenkins brings a wealth ... built and led teams advancing programs from scientific ... healthcare systems globally. "Annalisa brings ...
(Date:4/20/2015)... - Development of a Novel ... VOLVOX Platform - To be Presented on Tuesday, Apr ... Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody ... Apr 19, 1:00 PM EST Invictus Oncology ... announced that the company,s novel computational platform technology (VOLVOX) ...
(Date:4/20/2015)... Global Stem Cells Group today announced plans ... of aesthetic medicine experts and innovators. GSCG Advisory Board ... company’s brand new training course that combines facial fat ... , The course is designed to address the primary ... facial aging caused by volume loss. , The ...
(Date:4/17/2015)... Reed Technology and Information Services ... management, preparation, and submission to the U.S. Food and ... new Lot Distribution Report (LDR) service for manufacturers of ... with the FDA’s new rule on electronic submission of ... the volume and timing of particular biologics introduced to ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
... Group,("Simcere" or the "Company") (NYSE: SCR ), a ... China, today reported,unaudited financial results for the quarter ended March ... -- Total revenue increased to RMB442.5 million (US$64.8 million) ... of 2009 from RMB394.6 million for the corresponding, ...
... - Oncothyreon Inc. (Nasdaq: ONTY ) ... demonstrating the effectiveness of Oncothyreon,s PX-866 in a ... presented earlier today by William D. Hardie, M.D., ... Cincinnati, Ohio, at the American Thoracic Society International ...
... NASHVILLE, Tenn., May 18 Cumberland Pharmaceuticals announced ... for hospitals using Acetadote (acetylcysteine) ... overdose. (Photo: http://www.newscom.com/cgi-bin/prnh/20090518/CL18638 ... , the webcast provides hospital pharmacists and physicians, ...
Cached Biology Technology:Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 2Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 3Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 4Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 6Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 7Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 8Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 9Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 10Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 11Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 2Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 3Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R) 2Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R) 3
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... Bacteria can directly cause human blood and plasma to ... lost during the course of vertebrate evolution, according to ... of Allergy and Infectious Diseases, and Institut Pasteur in ... in Nature Chemical Biology . , The discovery ...
... designing and manufacturing biomedical sensors, healthcare and its related ... learn what to expect from this new and growing ... seminar set for Nov. 6, 2008, from 4:45-6 p.m., ... (ECE) Building, 141 Warren St, at the northwest corner ...
... in Italy have found bacteria in the root of ... the cosmetic and perfumery industries. These bacteria seem to ... change the molecular structure of the oil, giving it ... Studying the root of the tropical Vetiver grass ...
Cached Biology News:Nature study demonstrates that bacterial clotting depends on clustering 2NJIT seminar set for Nov. 6 to focus on bioelectronics -- emerging research area 2Bacteria manage perfume oil production from grass 2
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS ... picking systems This CLS number is a ... Cornings product number. If showing no availability ... number (D9314) or contact customer service for ...
Biology Products: